Skip to content
PeptideTech
Cart

Home / Research library / Liraglutide

Peptides

Liraglutide: molecular data, studies & sources

Liraglutide is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C172H265N43O51
Molecular weight (MW)
3751 g/mol
PubChem compound ID
16134956
Record title
Liraglutide

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 16134956 · retrieved 2026-09-21

2D molecular structure for Liraglutide, PubChem CID 16134956
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
InChIKey
YSDQQAXHVYUZIW-QCIJIYAXSA-N
SMILES
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O
Machine-readable PubChem source
Calculated molecular descriptors
Monoisotopic (exact) mass3748.9465 Da
Heavy atoms266
Hydrogen-bond donors54
Hydrogen-bond acceptors49
Rotatable bonds130
Topological polar surface area1513.8 Ų
Calculated logP (Crippen)-10.16
Rings6
Stereocenters31
Formal charge0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Liraglutide as an intervention. Studies that only measure the molecule as a biomarker are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

40 registered studies matched, 6 currently active or recruiting.

StudyPhase · statusConditionsSponsor · size
A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.NCT07301437 · start 2026-05-01 · primary completion 2027-08-31Phase 4Not Yet RecruitingOverweight and Obese AdultsThe Fourth Affiliated Hospital of Zhejiang University School of Medicine120 participants
Prospective, Randomized, Controlled Trial of Preoperative Use of Saxenda (Liraglutide) Additionally to Common Dietological Measures as Opposed to Dietological Measures AloneNCT06865365 · start 2025-05-01 · primary completion 2027-02-01Phase 4Not Yet RecruitingObesity, AdolescentMedical University of Vienna72 participants
Pilot Study of the Effect of Weight Loss by Pharmacotherapy on Chronic Pro-tumor Inflammatory CellsNCT05756764 · start 2023-06-01 · primary completion 2026-01-30Not applicableActive Not RecruitingObesityLouisiana State University Health Sciences Center in New Orleans30 participants
A Phase Ib/IIa, Single Ascending Dose Study of the Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes MellitusNCT05268237 · start 2023-04-25 · primary completion 2025-12Phase 1 / Phase 2RecruitingDiabete Type 2Biolingus15 participants
Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled StudyNCT03087032 · start 2019-01-10 · primary completion 2025-01-15Phase 4RecruitingType 2 Diabetes Patients · Overweight and Obesity · Hyperglycaemia (Diabetic)The First Affiliated Hospital of Xiamen University164 participants
Saxenda: Underlying Mechanisms and Clinical OutcomesNCT02944500 · start 2016-11 · primary completion 2027-06Phase 4Active Not RecruitingObesityBeth Israel Deaconess Medical Center28 participants
A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 DiabetesNCT06559722 · start 2024-08 · primary completion 2025-10Phase 3UnknownType 2 DiabetesTonghua Dongbao Pharmaceutical Co.,Ltd510 participants
Effect of Liraglutide on Different Parameters (Clinical , Metabolic and Hormonal) in Obese Women With Polycystic Ovary SyndromeNCT05965908 · start 2024-08-01 · primary completion 2025-11-30Phase 3CompletedPolycystic OvaryBeni-Suef University183 participants
An Open, Single Ascending Dose, Phase 1 Study to Assess the Pharmacokinetics, Safety, and Tolerability of NEX-22A, a Subcutaneous Prolonged-release Injection, in Male and Female Participants With Type 2 DiabetesNCT06439056 · start 2024-05-27 · primary completion 2025-07-18Phase 1CompletedType 2 DiabetesNanexa AB12 participants
Liraglutide for Management of Obesity in People Living With HIV on Dolutegravir-based Antiretroviral Therapy: a Single-arm Acceptability Study in South AfricaNCT06438146 · start 2024-05-02 · primary completion 2025-05Phase 4UnknownObesity · HIV InfectionsBrigham and Women's Hospital40 participants
Show 30 more registered studies
StudyPhase · statusConditionsSponsor · size
Pharmacological Treatment - An Overview of Its Role in Managing Childhood ObesityNCT07304141 · start 2023-12-20 · primary completion 2025-12-12Not applicableCompletedObesity (Disorder) · Child ObesityGöteborg University128 participants
Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and InfertilityNCT05952882 · start 2023-11-01 · primary completion 2025-12-31Phase 3UnknownPolycystic Ovary Syndrome · Obesity · Infertility, FemaleMỹ Đức Hospital188 participants
Obesity Treatment to Improve DiabetesNCT05390307 · start 2023-04-01 · primary completion 2024-01-01Not applicableCompletedType 1 DiabetesDasman Diabetes Institute60 participants
Comparison of Efficacy and Safety of POSE 2.0 Procedure Compared to GLP-1 Agonist in a Cohort of Patients for Management of Obesity: a Single-center Randomized Crossover-controlled TrialNCT05705388 · start 2023-01-16 · primary completion 2025-01-03Not applicableUnknownObesityEmirates Health Services (EHS)50 participants
Liraglutide Effectiveness in Preoperative Weight-loss for Patients With Severe Obesity Undergoing Bariatric-metabolic Surgery.NCT06201819 · start 2022-12-18 · primary completion 2023-03-18Phase 4CompletedWeight Loss · Bariatric Surgery Candidate · Obesity, MorbidHospital Civil Juan I. Menchaca37 participants
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 AnalogueNCT05767255 · start 2022-12-01 · primary completion 2023-08-30Phase 3UnknownDiabetes Mellitus, Type 2 Treated With InsulinHospital Universitario San Ignacio66 participants
Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Type 2 Diabetes (LIGHT-MCI): A Multicentre, Randomised Controlled Trial With An Extension PhaseNCT05313529 · start 2022-10-08 · primary completion 2025-12-31Not applicableCompletedType 2 Diabetes Mellitus · Mild Cognitive ImpairmentThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School396 participants
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of LY3537021 When Combined With GLP-1 Receptor Agonist in Healthy ParticipantsNCT05444569 · start 2022-08-08 · primary completion 2023-02-24Phase 1CompletedHealthyEli Lilly and Company47 participants
Efficacy of Liraglutide Therapy in Patients With an Ileal -Pouch Anal Anastomosis (IPAA) and Chronic High Bowel FrequencyNCT04763564 · start 2022-03-22 · primary completion 2023-10-16Phase 2TerminatedPouchitis · Irritable Pouch SyndromeUniversity of North Carolina, Chapel Hill8 participants
A Phase 1 Study of Liraglutide Injection and Victoza® in Healthy Chinese Subjects: An Open, Randomized, Single-Dose and Crossover StudyNCT05225974 · start 2021-07-16 · primary completion 2021-07-30Phase 1CompletedTherapeutic EquivalencyThe Affiliated Hospital of Qingdao University32 participants
Effects of Degludec/Liraglutide on Time in Range, Markers of Inflammation and Endothelial Dysfunction Compared to Scheme Insulin Basal Bolus, in a Population of Diabetic Inpatients and Possible Correlation With Intra-hospital Mortality RatesNCT05360537 · start 2021-04-01 · primary completion 2021-12-01Phase 4CompletedDiabetes Mellitus, Type 2University of Palermo100 participants
Megestrol Acetate Versus Liraglutide Plus Megestrol Acetate in Obese Women with Endometrial Atypical Hyperplasia: a Randomized Controlled Pilot Clinical StudyNCT04683237 · start 2021-03-20 · primary completion 2025-11-30Phase 2 / Phase 3WithdrawnAtypical Endometrial Hyperplasia · Obese · Fertility IssuesXiaojun ChenEnrollment not listed
Effects of the Glucagon Like-peptide 1 (GLP-1) Receptor Agonist Liraglutide on Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: a Randomized Controlled TrialNCT04881110 · start 2021-02-01 · primary completion 2022-12-31Phase 4CompletedType 2 Diabetes · Peripheral Arterial DiseaseUniversity of Campania Luigi Vanvitelli60 participants
Liraglutide for Low-responders After Bariatric SurgeryNCT04643301 · start 2020-12-21 · primary completion 2021-12-31Not applicableWithdrawnObesity · Obesity, MorbidZuyderland Medisch CentrumEnrollment not listed
A Prospective, Non-interventional, Single Arm Study Investigating Long-term Glycaemic Control in Patients With Type 2 Diabetes Initiating Xultophy® (IDegLira) in a Realworld Setting in ItalyNCT04666987 · start 2020-10-21 · primary completion 2022-12-30Not applicableCompletedDiabetes Mellitus, Type 2Novo Nordisk A/S359 participants
Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRINCT04311411 · start 2020-08-24 · primary completion 2022-12-16Phase 1CompletedObesity · OverweightEli Lilly and Company114 participants
Harmonizing RCT-Duplicate Emulations: A Real World Replication Program Analyzing Three Clinical Trials, CANVAS, LEADER, and SAVOR TIMI in Type 2 Diabetes MellitusNCT06099067 · start 2020-05-15 · primary completion 2023-08-31Not applicableCompletedType 2 Diabetes MellitusAstraZeneca239990 participants
Effects of Benaglutide on Weight and Gut Microbiota in Obese PatientsNCT03986008 · start 2019-12-01 · primary completion 2021-12-23Phase 3UnknownObesityXiangya Hospital of Central South University60 participants
Clinical Study on the Improvement of Diabetic Neuropathic Pain by LiraglutideNCT04137328 · start 2019-11-30 · primary completion 2022-11-30Not applicableUnknownDiabetic Neuropathic PainFudan University60 participants
Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or ObesityNCT04074161 · start 2019-09-11 · primary completion 2021-03-27Phase 3CompletedOverweight · ObesityNovo Nordisk A/S338 participants
Human Bioequivalence Test of Liraglutide InjectionNCT05029076 · start 2019-05-21 · primary completion 2019-06-01Phase 1CompletedType 2 DiabetesChia Tai Tianqing Pharmaceutical Group Co., Ltd.28 participants
Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled TrialNCT04046822 · start 2019-01-09 · primary completion 2020-01-09Phase 4UnknownObesity · Weight Loss · MicrobiomeFederico II University70 participants
A Multicenter Prospective Non-interventional Study Investigating the Treatment Effect of Xultophy® Intensification in a Real World Population With Type 2 Diabetes in United Arab EmiratesNCT03823339 · start 2019-01-29 · primary completion 2020-12-14Not applicableCompletedDiabetes Mellitus, Type 2Novo Nordisk A/S300 participants
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With ObesityNCT03757130 · start 2018-11-26 · primary completion 2019-12-16Phase 1CompletedObesityAmgen50 participants
Cardiovascular Outcomes, and Mortality in Danish Patients With Type 2 Diabetes Who Initiate Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA): A Danish Nationwide Comparative Effectiveness Study [EMPLACEtm]NCT03993132 · start 2018-10-01 · primary completion 2022-06-16Not applicableCompletedDiabetes Mellitus, Type 2Boehringer Ingelheim26774 participants
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese PatientsNCT03671733 · start 2018-09-01 · primary completion 2022-09-01Phase 3UnknownObesityXiangya Hospital of Central South University150 participants
Randomized Clinical Trial to Evaluate the Use of Liraglutide in Individuals With Brain Death and Anti-inflammatory and Anti-apoptotic Effects on Organs to be TransplantedNCT03672812 · start 2018-09-01 · primary completion 2019-12-10Phase 3CompletedBrain DeathHospital de Clinicas de Porto Alegre50 participants
Prospective, Multicentre, Open-label, Single-arm, Non-interventional Regulatory Post-marketing Surveillance(rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® (Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in KoreaNCT03560336 · start 2018-07-05 · primary completion 2020-12-02Not applicableCompletedObesity · OverweightNovo Nordisk A/S758 participants
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care DatabaseNCT03479762 · start 2018-04-20 · primary completion 2022-09-12Not applicableCompletedObesity · OverweightNovo Nordisk A/S105 participants
Effects of GLP-1 Receptor Agonist Treatment on Pulmonary Function and Quality of Life in Obese Patients With Chronic Obstructive Pulmonary Disease.NCT03466021 · start 2018-01-01 · primary completion 2020-05-31Phase 4CompletedPulmonary Disease, Chronic ObstructiveClaus Bogh Juhl40 participants

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

  1. Human study · PubMed trial index

    Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

    Rubino DM, Greenway FL, Khalid U et al. · JAMA · 2022

    PMID 35015037 · DOI: 10.1001/jama.2021.23619

  2. Human study · PubMed trial index

    Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.

    Fox CK, Barrientos-Pérez M, Bomberg EM et al. · The New England journal of medicine · 2025

    PMID 39258838 · DOI: 10.1056/NEJMoa2407379

  3. Human study · PubMed trial index

    A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

    Pi-Sunyer X, Astrup A, Fujioka K et al. · The New England journal of medicine · 2015

    PMID 26132939 · DOI: 10.1056/NEJMoa1411892

  4. Human study · PubMed trial index

    Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.

    Lundgren JR, Janus C, Jensen SBK et al. · The New England journal of medicine · 2021

    PMID 33951361 · DOI: 10.1056/NEJMoa2028198

  5. Human study · PubMed trial index

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

    Marso SP, Daniels GH, Brown-Frandsen K et al. · The New England journal of medicine · 2016

    PMID 27295427 · DOI: 10.1056/NEJMoa1603827

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

  1. Preclinical / laboratory research

    The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

    Secher A, Jelsing J, Baquero AF et al. · The Journal of clinical investigation · 2014

    PMID 25202980 · DOI: 10.1172/JCI75276

  2. Preclinical / laboratory research

    Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.

    Guo T, Yan W, Cui X et al. · Molecular medicine (Cambridge, Mass.) · 2023

    PMID 37770820 · DOI: 10.1186/s10020-023-00721-7

Liraglutide supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Liraglutide for sale: compare prices, sizes and forms from every tracked supplier →

SupplierRecorded packagesExample source listing
Amino USAUSD5mg Vial1 recorded offers5mg Vial · $51.00Checked Oct 7, 2026Supplier listing

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles